Is Ruxolitinib Tablets/Jiekewei a targeted or chemotherapy drug?

Many patients with myelofibrosis (MF) will be concerned about whether it is a targeted drug or a chemotherapy drug when they come into contact with ruxolitinib tablets/ruxolitinib (Ruxolitinib), which directly affects the psychology of drug use and expectations of side effects. Ruxolitinib is a small molecule oral JAK inhibitor that is a precision targeted drug rather than a chemotherapy drug in the traditional sense. Its mechanism of action is to selectively inhibit the Janus kinase 1 and 2 signaling pathways, thereby intervening in abnormal cytokine signaling and regulating abnormal bone marrow hematopoietic activity and inflammatory response. Compared with chemotherapy drugs that directly kill cells, ruxolitinib is more gentle and focuses on regulating abnormal signaling pathways to relieve symptoms and improve quality of life.

As a targeted drug, ruxolitinib's advantages lie in its specificity and long-term sustainability. During use, patients generally do not experience hair loss, severe nausea or acute bone marrow suppression that are common during chemotherapy, but they still need to pay attention to the risk of thrombocytopenia, anemia or infection. Such side effects can usually be controlled through monitoring and dose adjustment, and the drug is generally well tolerated. Experience shows that the advantage of targeted drugs is that they can be taken orally for a long period of time, which facilitates the management of chronic diseases. At the same time, they can achieve relatively stable effects in improving symptoms and improving quality of life.

Generally speaking, ruxolitinib tablets are targeted drugs rather than chemotherapy drugs, and its treatment concept emphasizes precise suppression of abnormal signals rather than systemic cell killing. Through long-term standardized medication and regular review, patients can maintain stability and comfort in daily life while relieving myelofibrosis-related symptoms. This also makes ruxolitinib an indispensable oral targeted therapy option in the modern management of myelofibrosis and related hematological diseases.

Reference materials:https://www.jakavi.com/